Dxcover Limited, developer of liquid biopsies for the early detection of cancer, has secured US patents for its groundbreaking Dxcover® Autosampler and the Dxcover® Brain Cancer Liquid Biopsy. The Glasgow-based company has developed an alternative approach to traditional blood sampling liquid biopsy for the early detection of cancer through its unique testing which uses attenuated...

As part of the next stage of development of Afon Technology, and in preparation for upcoming clinical trials in Wales, the company moved to a larger, state of the art laboratory facilities. These were formally opened in September and visited by leading Welsh politicians including Peter Fox MS (Member of the Welsh Parliament), Richard John, Leader...

PRESS RELEASE – for immediate release August 2021 DRAFT Early brain cancer detection breakthrough for Dxcover Blood test proves ability to identify really small brain tumours and gives hope of earlier detection and improved survival Dxcover acquires all IP for its Dxcover® Liquid Biopsy Technology and Multi Cancer Early Detection (MCED) Platform Early detection of...

Strathclyde University announces scientists, led by Dr Damion Corrigan, are developing a rapid, low cost and mass manufacturable saliva/nasal swab based biosensor test for COVID-19 inspired by the glucose test strips used to check blood sugar levels in people with diabetes. The electrochemical platform developed by Dr Corrigan’s team can provide a result in 2...